Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study

By afschroeder • August 7, 2025

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study. Dermatol Ther (Heidelb). 2025 Aug 6. doi: 10.1007/s13555-025-01466-3. Epub ahead of print. PMID: 40767996.

Tags: apremilast, Dermatology, disease burden, Phosphodiesterase 4 inhibitors, psoriasis, Publications, real-world, Topical drug administration

US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European Academy of Dermatology and Venereology

Kasperkiewicz M, Thapa M, Adotama P, Tomayko MM, Culton DA. US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European[...]

Single-cell and spatial profiling reveal cDC2A-CXCL13+CD8+ T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus

Jiang R, Bogle R, Xing X, Kirma J, Fox J, Harms PW, Do T, Billi AC, Kahlenberg JM, Modlin RL, Teles R, West J, Mangold[...]

Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis

Conde G, Carmenate Y, Bello G, Armstrong AW. Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis. J Dermatol. 2026 Mar 13. doi:[...]